DNDi Utilizing Pinnacle 21 Enterprise (P21E), Certara’s Data Science platform for Biostatistics, Data Management, and Data Standards to Streamline Clinical Data Flow PRINCETON, NJ/NAIROBI, KE, 2023年7月31日 – Certara,…
What is model-informed drug development (MIDD), and why is it so critical to informing the development of safer and more effective new drugs? During this event, you will uncover ways…
You are having a good day as a quality assurance professional at a small pharmaceutical company until you open an email from your company president asking for an explanation. She…
Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform PRINCETON, N.J.— 2023年6月12日. Certara®, the global leader in biosimulation, today announced the launch of version 8.4…
安全性と有効性に優れた治療薬へのアクセスは⼩児患者にとって⾮常に深刻な問題です。小児に処方される医薬品の60～70％は適応外使用なのが現実です。In Japan, only 30% of new drugs are approved for…
Tailored biometrics capabilities that cover the full drug development continuum (pre-clinical through NDA/BLA).
© 2025 Certara. All Rights Reserved. | 個人情報保護
